Live Breaking News & Updates on Peer exchange

Stay informed with the latest breaking news from Peer exchange on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Peer exchange and stay connected to the pulse of your community

NATALEE: Ribociclib and Endocrine Therapy in HR+/HER2- Early Breast Cancer

Aimee Keegan, PharmD, BCOP, discusses key unmet needs that the NATALEE trial addresses for patients with HR+/HER2- early breast cancer.

Aimee-keegan , Peer-exchange ,

Institutional Insights on CDK4/6 Inhibitor Adherence in Breast Cancer

Aimee Keegan, PharmD, BCOP, discusses how her institution optimizes patient adherence to CDK4/6 inhibitors, highlighting resources including their in-house specialty pharmacy.

Aimee-keegan , Peer-exchange ,

Optimizing Adherence to CDK4/6 Inhibitors in Metastatic Breast Cancer

Focusing on metastatic breast cancer, Aimee Keegan, PharmD, BCOP, provides clinical insights on ensuring optimal adherence to CDK4/6 inhibitors.

Aimee-keegan , Peer-exchange ,

Concluding Thoughts on Ph+ ALL Treatment

Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.

Philadelphia , Pennsylvania , United-states , Jamesk-mccloskey , Jonathan-abbas , Ryan-haumschild , Vivian-tambe-ebot , Elias-jabbour , Peer-exchange , Vivian-tambe-ebot-tar , Transplant- , Chemotherapy

The Future of Ph+ ALL Treatments

Medical doctors discuss the future of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) and their five-year outlook for advancements and potential cures for the disease.

Philadelphia , Pennsylvania , United-states , Jamesk-mccloskey , Jonathan-abbas , Ryan-haumschild , Vivian-tambe-ebot , Elias-jabbour , Peer-exchange , Vivian-tambe-ebot-tar , Transplant , Chemotherapy

Ethical Implications of Patient Access Restrictions

Jessica Nance, MD, MS, and Emma Ciafaloni, MD, FAAN, discuss ethical dilemmas, exploring how patient subgroup restrictions on orphan drugs can impact access and cost control.

Kimberlyc-chen , Emma-ciafaloni , Ryan-haumschild , Mary-pak , Peer-exchange , Jessica-nance , Collaboration , Gene-therapy , Managed-care , Patient-access , Healthcare , Clinical-data

Enhancing Collaboration for Patient-Centered Care in Rare Diseases

A panel of experts discuss improving collaboration between health systems and managed care organizations to ensure optimal outcomes for patients with rare diseases.

Emma-ciafaloni , Kimberlyc-chen , Mary-pak , Ryan-haumschild , Peer-exchange , Jessica-nance , Collaboration , Gene-therapy , Managed-care , Patient-access , Healthcare , Clinical-data

Innovative Payment Models for Gene Therapies

Kimberly C. Chen, DO, MSHLM, discusses subscription models and warranties for cell and gene therapies, exploring their impact on patient access and financial sustainability.

Mary-pak , Ryan-haumschild , Emma-ciafaloni , Kimberlyc-chen , Peer-exchange , Jessica-nance ,

CAR T-Cell Therapy: Managing Adverse Events and Assessing Patient Response in Lymphoma

Clinical insights on managing adverse events associated with CAR T-cell therapy and measuring patient response, highlighting a phase 2 trial on prophylactic anakinra.

Loria-leslie , Jamesk-mccloskey , Lori-leslie , John-theurer-cancer-center , Peer-exchange , Research-programs , Hackensack-university-medical-center , Hackensack-university-medical , Associate-professor , Indolent-lymphoma ,

Interpreting Clinical Data to Guide Coverage Decisions for Rare Disease Therapies

Health care professionals discuss the challenges related to developing and interpreting clinical data for rare disease therapies to guide payer coverage decisions.

Mary-pak , Ryan-haumschild , Emma-ciafaloni , Kimberlyc-chen , Peer-exchange , Jessica-nance ,